-
33611.浅析国外基本药物目录遴选的成功经验
[医药制造业] [2013-06-26]
目的 研究国外基本药物目录的遴选经验，为我国的基本药物目录遴选提供参考。方法 采用文献研究法。结果与结论 通过借鉴WHO、澳大利亚、泰国的成功经验，应从细化遴选原则、提高遴选透明度和建立科学的遴选体系3个方面来不断完善我国的遴选环节。
关键词：基本药物目录；遴选；国外经验
-
33612.日本仿制药品质一致性再评价介绍及对我国的启示
[医药制造业] [2013-06-26]
目的：为我国仿制药质量一致性评价工作提供参考。方法：介绍日本仿制药品质一致性再评价的方法，探讨其对我国仿制药质量一致性评价的借鉴意义。结果与结论：日本仿制药品质一致性再评价的方法对我国仿制药质量一致性评价工作具有参考意义。
关键词：仿制药；质量；评价
-
33613.中国化工导报（2013年6月21日）
[医药制造业,石油加工、炼焦和核燃料加工业,化学原料和化学制品制造业] [2013-06-25]
Foreign trade of western medicine is expected to grow ranging 8% to 10% in 2013. Trade surplus is expected to shrink continually as import growth will be higher than export increase. For China's API manufacturers, how to accelerate industrial restructuring and build international competitiveness is a significant problem in the new era.ForChina's API manufacturers, how to accelerate industrial restructuring and build international competitiveness is a significant problem in the new era.
关键词：制药；药物；双酚A；双酚基丙烷（BPA）；产出
-
33614.中药民族药成为贵州医药工业主导
[医药制造业] [2013-06-20]
关键词：中药；民族药；工业主导
-
33615.安徽淮南市多措并举促进医药经济快速发展
[医药制造业] [2013-06-20]
关键词：医药产业；医药经济；措施
-
33616.益佰制药溢价56倍购微利资产盈利预测变数大
[医药制造业] [2013-06-20]
关键词：益佰制药；百祥制药；收购；盈利预测
-
33617.中国民企原创药专利首次授权海外顶尖制药集团
[医药制造业] [2013-06-20]
关键词：民企；原创药；专利；制药
-
33618.神威药业4个处方药上市
[医药制造业] [2013-06-20]
关键词：神威药业；处方药；上市
-
33619.医药企业原料药出口市场研究
[医药制造业] [2013-06-19]
随着经济实力加强和全球经济一体化的实现，我国原料药的生产和出口比重也越来越大，在世界原料药是市场中占据了举足轻重的地位，是原料药生产和出口的大国。但是，我国原料药的出口仍然要面对很多贸易上的考验和难关，并且，金融危机和全球经济的缓慢复苏也给我国原料药的出口带来了巨大的挑战。本文主要从经济学和国际贸易和管理学的角度出发，主要阐述了我国医药企业原料药的国内外市场现状、市场优势和面临挑战以及应当采取的战略对策。
关键词：医药企业；原料药；出口市场
-
33620.亚太报告——药品
[医药制造业] [2013-06-17]
In the past six months, drug price cuts continued to reverberate across the Asia-Pacific. Major countries such as China, India and Australia announced further drug price reductions. Leading Asian drugmakers posted a mixed bag of earnings. Takeda Pharmaceutical (TSE: 4502) and Dr Reddy’s Laboratories (BSE: 500124) for example, posted double-digit declines in net profit while others such as Lupin Ltd (NYSE: MYL) saw significant growth as its profits rose more than 40% year-on-year due to strong sales growth in their US market. The shares prices of 11 leading Asian pharmaceutical companies posted average gains of approximately 22% over the six-month period under review from September 4, 2012, to February 26, 2013. Ten out of the 11 companies assessed by Mergent saw their share prices rise over the period, with Dainippon Sumitomo Pharma’s stock price rising the most at nearly 58%. In the past six months, pharmaceutical merger and acquisition activity in the region somewhat slowed down, compared to the strong level of merger and acquisition activity (M&A) seen in the first half of 2012.
关键词：亚太地区；药品；市场环境；市场趋势
027-87841330